The study is focused on adult T1D patients with impaired hypoglycemic awareness and severe hypoglycemia.

All six patients treated with VX-880 had undetectable insulin secretion and a history of recurrent severe hypoglycemic events in the year prior to treatment.

Following treatment, all patients demonstrated restored insulin secretion, improved glycemic control, improved time-in-range, reduction or elimination of exogenous insulin usage, and complete absence of severe hypoglycemic events in the post-day 90 evaluation period, the ADA said.

Dr. Trevor Reichman, PhD, surgical director of pancreas and islet cell transplantation at the University of Toronto, presented results for the phases 1/2, multicenter, single-arm clinical trial at the 83rd Scientific Sessions of the ADA, held in San Diego from June 23 to June 26.

“These new findings demonstrate the potential of stem cell-derived islets as a future treatment for patients with type 1 diabetes, signaling a new era that could potentially remove the need for exogenously administered insulin to achieve glycemic control,” Reichman said in a statement.

The study has been expanded to additional sites that are active and enrolling in Norway, Switzerland, and the Netherlands.

News Source: